Pressmeddelanden

PILA PHARMA ANNOUNCES INITIATION OF STUDY IN PRECLINICAL RESEARCH COLLABORATION IN CARDIOVASCULAR DISEASE PILA PHARMA AB (publ) ("PILA PHARMA" or the "Company") today announces the initiation of the study associated to the co-sponsorship of the research collaboration with the Researc...
PILA PHARMA INVITES TO NORDIC INVESTOR MEETINGS PILA PHARMA AB (publ) ("PILA PHARMA" or the "Company") (FN STO: PILA) hereby invites you to participate in these upcoming Nordic investor events:
PILA PHARMA AB Chairman & CEO increase their holdings PILA PHARMA AB (publ) ("PILA PHARMA" or the "Company"), (FN STO: PILA), today announces that Chairman of the Board, Dorte X. Gram and CEO Gustav H. Gram have purchased additional...
PILA PHARMA TO PARTICIPATE IN DANISH INVESTMENT PODCAST "MILLIONÆRKLUBBEN" PILA PHARMA AB (publ) (FN STO: PILA) hereby invites you to view and/or listen to the broadcast from todays episode of "Millionærklubben" (Millionaire's Club) where PILA PHARMA's...
REG MAR
PILA PHARMA ANNOUNCES SELECTION OF CLINICAL TRIAL SITE AND DECISION TO SEEK SCIENTIFIC ADVICE FOR OPTIMIZED PP-CT03 STUDY DESIGN PILA PHARMA AB (publ) (FN STO:PILA) today announces the selection of the principal investigator, Professor Mark Evans and Cambridge University Hospital as principal clinical tria...
REG MAR
PILA PHARMA ANNOUNCES PROGRESSION AND CO-SPONSORSHIP OF PRECLINICAL RESEARCH COLLABORATION IN CARDIOVASCULAR DISEASE PILA PHARMA AB (publ) ("PILA PHARMA" or the "Company") today announces the co-sponsorship of the research collaboration with the Research Group of Professor Dick Wågsäter, Uppsal...
Visa fler pressmeddelanden

Rapporter

Video

Finansiell kalender

Bokslutskommuniké 2024 Bokslutskommuniké
Årsredovisning Årsredovisning
Halvårsrapport 2025 Delårsrapport

Om PILA PHARMA

Prenumerera

Få löpande information från PILA PHARMA via e-post.

Handelsinformation

Kurs ()
Förändring ()
Marknad Nasdaq First North Growth Market Kortnamn PILA ISIN-kod SE0015988274 Certified Adviser Aqurat Fondkommission